ArticleNature communications2026
Proteomics-based machine learning model for predicting secondary infection in HBV-related liver failure.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Plasma proteomic signatures associated with abdominal aortic aneurysm presence, growth, and risk of mortality.Scientific reports · 2026Article
- A machine learning model for 90-day mortality prediction in hepatitis B virus-related acute-on-chronic liver failure: the pivotal role of CALLY index.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with Hepatitis B Virus-related liver failure are highly vulnerable to secondary infections (SI), yet early predictive tools remain limited. In this work, we aim to develop and validate a plasma proteomics-based model for early SI risk assessment. In a prospective multicenter study, 114 patients are enrolled in the discovery cohort, 60 each in two validation cohorts. Untargeted proteomics is used to identify SI-related proteins, followed by Minimum Redundancy Maximum Relevance based feature selection and logistic regression modeling. Targeted proteomics and ELISA are applied for external validation. Inflammatory and coagulation pathway dysregulation is strongly associated with SI. A final model including Lysozyme (LYZ), Calmodulin 1 (CALM1), Serpin Family D Member 1 (SERPIND1), Dermatopontin (DPT), total bilirubin, and AST show excellent discrimination (area under the receiver operating characteristic curve (AUROC) 0.980 in discovery; 0.873 in validation), outperforming C-reactive protein (CRP), white blood cell (WBC), and Neutrophil percentage (NE%). It also predicts 28-day mortality better than Chronic Liver Failure-Consortium Acute-on-Chronic Liver Failure score (CLIF-C ACLF) and Model for End-Stage Liver Disease (MELD). ELISA measurements in validation cohort 2 yield consistent trends, and an ELISA-based model achieve an AUROC of 0.883. This proteomics-derived model reliably identifies patients at high SI risk and supports early clinical intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.